Open AccessNecrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma
Author(s) -
Mehmet Ali Nahit Şendur,
Sercan Aksoy,
Nuriye Özdemir,
Nurullah Zengi̇n
Publication year - 2014
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.125195
Subject(s) - bevacizumab , medicine , fasciitis , colorectal cancer , vascular endothelial growth factor , monoclonal antibody , metastasis , adenocarcinoma , monoclonal , dermatology , oncology , gastroenterology , cancer , vegf receptors , surgery , antibody , chemotherapy , immunology
Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.